Astrazeneca PLC with ticker code (AZN) have now 5 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 70 and 59.5 with a mean TP of 66.98. Given that the stocks previous close was at 58.13 this is indicating there is a potential upside of 15.2%. The 50 day moving average now sits at 58.24 and the 200 day MA is 58.34. The market capitalisation for the company is $187,728m. Company Website: https://www.astrazeneca.com
The potential market cap would be $216,308m based on the market concensus.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. The company markets various products in the therapeutic areas of oncology, respiratory and immunology, rare diseases, and other areas, as well as in cardiovascular, renal, and metabolism (CVRM) areas. It is also involved in the development of products in oncology, CVRM, respiratory and immunology, rare diseases, and other and COVID-19 areas. The company sells its products to primary care and specialty care physicians through local marketing companies, distributors, and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has agreements with Nexium Authorised Generics; TerSera Therapeutics LLC, as well as collaboration with Daiichi Sankyo; FibroGen; and Merck & Co. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
